Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. Co.'s lead clinical candidate, APVO436 is an ADAPTIR bispecific immunotherapeutic protein targeting CD123, a cell surface receptor highly expressed on several hematological malignancies and CD3, a component of the T-cell receptor. ALG.APV-527 is an investigational bispecific ADAPTIR candidate, partnered with Alligator Bioscience AB, featuring a mechanism of action designed to simultaneously target 4-1BB (CD137) and 5T4, a tumor antigen overexpressed in a number of different types of cancer. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate. The APVO stock yearly return is shown above.
The yearly return on the APVO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the APVO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|